Close Menu

NEW YORK – Cancer Genetics reported after the close of the market on Wednesday that its first quarter revenues fell 22 percent year over year, mainly due to a non-recurring IP licensing agreement a year ago.

For the three months ended March 31, Rutherford, New Jersey-based Cancer Genetics posted total revenues of $1.4 million versus $1.8 million in the same quarter the year before. In Q1 2019, the firm had $300,000 in revenue from an IP license agreement that was unrelated to its ongoing discovery services business.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.